Literature DB >> 27770308

The surgical treatment of acromegaly.

Michael Buchfelder1, Sven-Martin Schlaffer2.   

Abstract

PURPOSE: Surgical extraction of as much tumour mass as possible is considered the first step of treatment in acromegaly in many centers. In this article the potential benefits, disadvantages and limitations of operative acromegaly treatment are reviewed.
METHODS: Pertinent literature was selected to provide a review covering current indications, techniques and results of operations for acromegaly.
RESULTS: The rapid reduction of tumour volume is an asset of surgery. To date, in almost all patients, minimally invasive, transsphenoidal microscopic or endoscopic approaches are employed. Whether a curative approach is feasible or a debulking procedure is planned, can be anticipated on the basis of preoperative magnetic resonance imaging. The radicality of adenoma resection essentially depends on localization, size and invasive character of the tumour. The normalization rates of growth hormone and IGF-1 secretion, respectively, depend on tumour-related factors such as size, extension, the presence or absence of invasion and the magnitude of IGF-1 and growth hormone oversecretion. However, also surgeon-related factors such as experience and patient load of the centers have been shown to strongly affect surgical results and the rate of complications. As compared to most medical treatments, surgery is relatively cheap since the costs occur only once and not repeatedly. There are several new technical gadgets which aid in the surgical procedure: navigation and variants of intraoperative imaging.
CONCLUSIONS: For the mentioned reasons, current algorithms of acromegaly management suggest an initial operation, unless the patients are unfit for surgery, refuse an operation or only an unsatisfactory resection is anticipated. A few suggestions are made when a re-operation could be considered.

Entities:  

Keywords:  Acromegaly; Complications; Debulking; Operation; Pituitary tumour; Transsphenoidal surgery

Mesh:

Substances:

Year:  2017        PMID: 27770308     DOI: 10.1007/s11102-016-0765-7

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  68 in total

1.  Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission.

Authors:  P De; D A Rees; N Davies; R John; J Neal; R G Mills; J Vafidis; J S Davies; M F Scanlon
Journal:  J Clin Endocrinol Metab       Date:  2003-08       Impact factor: 5.958

Review 2.  Debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogues.

Authors:  John Wass
Journal:  Eur J Endocrinol       Date:  2005-05       Impact factor: 6.664

Review 3.  Treatment of pituitary tumors: surgery.

Authors:  Michael Buchfelder
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

4.  Fully endoscopic endonasal vs. transseptal transsphenoidal pituitary surgery.

Authors:  M S Kabil; J B Eby; H K Shahinian
Journal:  Minim Invasive Neurosurg       Date:  2005-12

5.  Repeat endoscopic transsphenoidal surgery for acromegaly: remission and complications.

Authors:  Thomas J Wilson; Erin L McKean; Ariel L Barkan; William F Chandler; Stephen E Sullivan
Journal:  Pituitary       Date:  2013-12       Impact factor: 4.107

6.  Intraoperative Magnetic Resonance Imaging During Endoscopic Transsphenoidal Surgery of Growth Hormone-Secreting Pituitary Adenomas.

Authors:  David Netuka; Martin Májovský; Václav Masopust; Tomáš Belšán; Josef Marek; Michal Kršek; Václav Hána; Jana Ježková; Václav Hána; Vladimír Beneš
Journal:  World Neurosurg       Date:  2016-05-03       Impact factor: 2.104

7.  Intraoperative magnetic resonance imaging-assisted transsphenoidal pituitary surgery in patients with acromegaly.

Authors:  David Bellut; Martin Hlavica; Christoph Schmid; René L Bernays
Journal:  Neurosurg Focus       Date:  2010-10       Impact factor: 4.047

8.  Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.

Authors:  Annamaria Colao; Roberto Attanasio; Rosario Pivonello; Paolo Cappabianca; Luigi M Cavallo; Giovanni Lasio; Alessandro Lodrini; Gaetano Lombardi; Renato Cozzi
Journal:  J Clin Endocrinol Metab       Date:  2005-11-01       Impact factor: 5.958

9.  Determinants of clinical outcome and survival in acromegaly.

Authors:  C Rajasoorya; I M Holdaway; P Wrightson; D J Scott; H K Ibbertson
Journal:  Clin Endocrinol (Oxf)       Date:  1994-07       Impact factor: 3.478

10.  Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.

Authors:  B Swearingen; F G Barker; L Katznelson; B M Biller; S Grinspoon; A Klibanski; N Moayeri; P M Black; N T Zervas
Journal:  J Clin Endocrinol Metab       Date:  1998-10       Impact factor: 5.958

View more
  11 in total

1.  Predictors of surgical outcome and early criteria of remission in acromegaly.

Authors:  Ximene Antunes; Nina Ventura; Gustavo Bittencourt Camilo; Luiz Eduardo Wildemberg; Andre Guasti; Paulo José M Pereira; Aline Helen Silva Camacho; Leila Chimelli; Paulo Niemeyer; Mônica R Gadelha; Leandro Kasuki
Journal:  Endocrine       Date:  2018-04-06       Impact factor: 3.633

2.  The therapeutic response of somatotropinomas according to the T2-weighted signal intensity on the MRI.

Authors:  Carla-Liana Scânteie; Daniel-Corneliu Leucuţa; Cristina Ghervan
Journal:  Med Pharm Rep       Date:  2021-10-30

3.  Implications of Heterogeneity of Epithelial-Mesenchymal States in Acromegaly Therapeutic Pharmacologic Response.

Authors:  Joan Gil; Montserrat Marques-Pamies; Elena Valassi; Araceli García-Martínez; Guillermo Serra; Cristina Hostalot; Carmen Fajardo-Montañana; Cristina Carrato; Ignacio Bernabeu; Mónica Marazuela; Helena Rodríguez-Lloveras; Rosa Cámara; Isabel Salinas; Cristina Lamas; Betina Biagetti; Andreu Simó-Servat; Susan M Webb; Antonio Picó; Mireia Jordà; Manel Puig-Domingo
Journal:  Biomedicines       Date:  2022-02-16

4.  Trends in surgery, hospital admissions and imaging for pituitary adenomas in Australia.

Authors:  Sjorjina Crowther; R Louise Rushworth; Wayne Rankin; Henrik Falhammar; Liza K Phillips; David J Torpy
Journal:  Endocrine       Date:  2017-11-04       Impact factor: 3.633

5.  Patient Characteristics, Diagnostic Delays, Treatment Patterns, Treatment Outcomes, Comorbidities, and Treatment Costs of Acromegaly in China: A Nationwide Study.

Authors:  Xiaopeng Guo; Kailu Wang; Siyue Yu; Lu Gao; Zihao Wang; Huijuan Zhu; Bing Xing; Shuyang Zhang; Dong Dong
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-01       Impact factor: 5.555

6.  Predicting Subtype of Growth Hormone Pituitary Adenoma based on Magnetic Resonance Imaging Characteristics.

Authors:  Chen-Xi Liu; Sheng-Zhong Wang; Li-Jun Heng; Yu Han; Yu-Hui Ma; Lin-Feng Yan; Ying Yu; Wen Wang; Yu-Chuan Hu; Guang-Bin Cui
Journal:  J Comput Assist Tomogr       Date:  2022 Jan-Feb 01       Impact factor: 1.826

7.  Machine learning-based clinical outcome prediction in surgery for acromegaly.

Authors:  Olivier Zanier; Matteo Zoli; Victor E Staartjes; Federica Guaraldi; Sofia Asioli; Arianna Rustici; Valentino Marino Picciola; Ernesto Pasquini; Marco Faustini-Fustini; Zoran Erlic; Luca Regli; Diego Mazzatenta; Carlo Serra
Journal:  Endocrine       Date:  2021-10-12       Impact factor: 3.633

Review 8.  Surgery for acromegaly: Indications and goals.

Authors:  David P Bray; Sai Mannam; Rima S Rindler; Joseph W Quillin; Nelson M Oyesiku
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-04       Impact factor: 6.055

9.  Usefulness of the Texture Signatures Based on Multiparametric MRI in Predicting Growth Hormone Pituitary Adenoma Subtypes.

Authors:  Chen-Xi Liu; Li-Jun Heng; Yu Han; Sheng-Zhong Wang; Lin-Feng Yan; Ying Yu; Jia-Liang Ren; Wen Wang; Yu-Chuan Hu; Guang-Bin Cui
Journal:  Front Oncol       Date:  2021-07-07       Impact factor: 6.244

10.  Reversibility of Cardiac Involvement in Acromegaly Patients After Surgery: 12-Month Follow-up Using Cardiovascular Magnetic Resonance.

Authors:  Xiaopeng Guo; Yihan Cao; Jian Cao; Xiao Li; Peijun Liu; Zihao Wang; Lu Gao; Xinjie Bao; Bing Xing; Yining Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-21       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.